ECO Animal Health Wins Early EU Approval for New Poultry Vaccine

Eco Animal Health ( (GB:EAH) ) has provided an announcement.

ECO Animal Health Group has secured European Union marketing authorisation for ECOVAXXIN MS, its new poultry vaccine targeting Mycoplasma synoviae, more than a month earlier than expected. The approval marks the first commercial launch from the company’s innovative R&D portfolio and is a strategic milestone that strengthens its position in the poultry health segment, addressing a disease that can cut egg production by 5–10% and cause significant economic losses for layer and breeder operations; ECO plans to outline its EU commercial launch strategy for the vaccine in early 2026.

The most recent analyst rating on (GB:EAH) stock is a Buy with a £123.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.

Spark’s Take on GB:EAH Stock

According to Spark, TipRanks’ AI Analyst, GB:EAH is a Outperform.

Eco Animal Health’s overall stock score is driven by strong technical momentum and positive corporate events, indicating confidence in future growth. However, the high valuation and inconsistent financial performance temper the score, suggesting potential risks if growth expectations are not met.

To see Spark’s full report on GB:EAH stock, click here.

More about Eco Animal Health

ECO Animal Health Group is a UK-headquartered global animal health company specialising in branded veterinary pharmaceuticals, particularly antibiotics and vaccines for pigs and poultry. With more than 200 employees, R&D and manufacturing operations, and marketing authorisations in over 70 countries, its lead product is Aivlosin, a patented treatment for respiratory and intestinal diseases in pigs and poultry, supported by a maturing proprietary R&D pipeline.

Average Trading Volume: 73,027

Technical Sentiment Signal: Buy

Current Market Cap: £66.07M

Learn more about EAH stock on TipRanks’ Stock Analysis page.